Search
forResearch 10 of 1000+
- Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus
- Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
- Clascoterone: First Approval
- Class III Peroxidases PRX01, PRX44, and PRX73 Control Root Hair Growth in Arabidopsis thaliana
- Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation
- Use of topical clascoterone for the treatment of hidradenitis suppurativa
- Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
- Inhibition of class I HDACs preserves hair follicle inductivity in postnatal dermal cells
- Class III peroxidases PRX01, PRX44, and PRX73 potentially target extensins during root hair growth in Arabidopsis thaliana
Learn 1 of 12
All learn results →Community 10 of 181
- Clascoterone Phase 3 Results and Efficacy
- Why isn’t Clascoterone being discussed more?
- Winlevi Clascoterone- resultssss
- Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)
- Clascoterone full results 2026
- Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?
- Clascoterone might be the Finasteride for female pattern hair loss.
- Clascoterone won't be available until q4 2027 at the earliest per the newest Cosmo Pharma newsletter
- How to mix raw Clascoterone (CB-03-01)?
- Clascoterone Scalp 2 Results in July?